Defendant
2 cases as defendant.
I'll verify the company profile details with web search.
Company overview. Pfizer Inc. (NYSE: PFE), commonly "Pfizer," is a publicly traded, research-based biopharmaceutical company headquartered in New York, NY. It was founded in 1849 by Charles Pfizer and Charles Erhart and incorporated in Delaware in 1942. It is a standalone public company, not a subsidiary. Scale is large: its 2024 Form 10-K reported ~5.67 billion shares outstanding and non-affiliate voting stock value of roughly $158 billion as of mid-2024; employee counts cited in public sources run around 88,000 and FY2024 revenue around $58.5 billion, though figures vary by source and period.
Products / services. Pfizer discovers, develops, manufactures and markets human medicines and vaccines. Therapeutic focus areas include oncology, vaccines, internal medicine, inflammation and immunology, and rare disease. Major marketed products include the COVID-19 vaccine Comirnaty (with BioNTech), the antiviral Paxlovid, the pneumococcal vaccine franchise Prevnar, the anticoagulant Eliquis, and oncology assets broadened by the 2023 Seagen acquisition. The company also operates contract manufacturing. It is an operating company, not a non-practicing entity.
Patent-litigation posture. In the tracked data Pfizer appears only as a defendant (2 cases, 0 as plaintiff) — the profile of a large operating company being sued rather than asserting. Both tracked entries are the same action, filed 2023-04-04 in the U.S. District Court for the District of New Jersey (Newark), Pfizer's home forum rather than a plaintiff-friendly venue such as the Eastern District of Texas.
Notable case. Arbutus Pharma Corp. (f/k/a Arbutus Biopharma Corp.) et al. v. Pfizer Inc. et al., No. 3:23-cv-01876 (D.N.J.). Plaintiffs — Arbutus, a Nasdaq-listed clinical-stage biopharma, and its licensee Genevant Sciences — assert five U.S. patents (including 9,504,651; 8,492,359; 11,141,378; 11,298,320; 11,318,098) covering lipid nanoparticle (LNP) delivery technology used in Comirnaty, seeking damages rather than an injunction. Pfizer and BioNTech counterclaimed for invalidity and non-infringement and attribute the LNP technology to Acuitas Therapeutics. Related Arbutus/Genevant actions against Moderna (D. Del.) and later filings in Canada and the UPC involve overlapping patents.
Arbutus and Genevant sued Pfizer and BioNTech in D.N.J. over Comirnaty, asserting 11141378 plus 9504651, 8492359, 11298320, and 11318098. The case remains pending with claim construction on September 9, 2025, and ongoing discovery as of April 26, 2026.
Arbutus and Genevant asserted five LNP patents, including the '359 patent, against Pfizer and BioNTech over Comirnaty. The action remains pending after a September 2025 claim construction ruling and was carved out of the Moderna settlement.